Egrifta (Tesamorelin) Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What Is Tesamorelin and Why Does Access Matter?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing factor (GRF). It binds pituitary GRF receptors and stimulates pulsatile growth hormone (GH) secretion, which in turn reduces visceral adipose tissue (VAT) in HIV-positive adults who develop lipodystrophy from long-term antiretroviral therapy (ART).

The FDA approved the original Egrifta formulation in November 2010, and a stabilized, room-temperature-stable reformulation called Egrifta SV was approved in July 2019. The FDA approval history is documented on the agency's drug database.

Why Access Is a Persistent Problem

HIV-associated lipodystrophy affects an estimated 40 to 50% of patients on long-term ART, according to data compiled by the NIH. Prevalence estimates are summarized at the National Library of Medicine. Despite this frequency, Egrifta remains costly and tightly defined by its label indication, leaving three groups of patients particularly vulnerable:

1. People with HIV who meet clinical criteria but whose insurer denies coverage.
2. Patients outside the approved indication (for example, growth-hormone-deficient adults without HIV) who seek tesamorelin off-label.
3. Uninsured or underinsured individuals whose monthly out-of-pocket cost can exceed $5,000.

What the FDA-Approved Label Actually Covers

The Prescribing Information states: "EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy." This single indication controls both insurance coverage decisions and the scope of any compassionate-use or expanded-access pathway. Off-label use for body-composition improvement in non-HIV populations is not supported by the approved label, which directly shapes what Theratechnologies can offer through formal programs.

Compassionate Use and Expanded Access: The Regulatory Framework

Defining Expanded Access Under 21 CFR Part 312

The FDA's expanded-access regulations (21 CFR Part 312, Subpart I) allow patients with serious conditions to access investigational or approved drugs outside of clinical trials when no comparable alternative exists. The FDA's expanded-access page explains the three pathways: individual, intermediate, and treatment IND. For an already-approved drug like tesamorelin, individual expanded-access requests are still possible when a patient falls outside the label, but the sponsor (Theratechnologies) must agree to supply the drug and file an IND amendment or a separate expanded-access IND.

Does Theratechnologies Have an Open Compassionate-Use Program?

As of January 2026, Theratechnologies has not announced a standing, open-enrollment compassionate-use or expanded-access protocol for tesamorelin in the United States. The company's patient-support infrastructure is channeled primarily through TheraCare, which is a reimbursement-assistance program rather than a clinical-trial or IND-based compassionate-use pathway.

Patients who believe they have a compelling medical need outside the label should ask their prescribing physician to contact Theratechnologies Medical Affairs directly and, in parallel, submit an individual expanded-access request through the FDA's online portal. The FDA reports a median physician-response time of less than one business day for urgent individual requests. The FDA's how-to guide for individual patient access is available here.

Active Clinical Trials as an Alternative Route

Enrollment in a registered clinical trial is sometimes the most straightforward path to accessing tesamorelin outside its approved indication. Searching ClinicalTrials.gov for "tesamorelin" in January 2026 returns studies examining the drug in non-alcoholic steatohepatitis (NASH), cognitive function in HIV, and abdominal fat in non-HIV populations. ClinicalTrials.gov tesamorelin search results are publicly available. Patients interested in these trials should discuss eligibility with their provider before assuming they qualify; most trials have strict inclusion and exclusion criteria.

The TheraCare Patient Support Program

TheraCare is Theratechnologies' branded hub for patient and prescriber support in the United States. It combines three distinct services: reimbursement navigation, co-pay assistance, and free-drug supply for qualifying uninsured patients.

Reimbursement Navigation

TheraCare case managers help providers prepare prior-authorization documentation, draft appeal letters when an insurer denies coverage, and identify alternative funding sources (ADAP, state Medicaid, 340B). Call 1-888-281-8862 Monday through Friday during business hours.

Co-Pay Assistance Card

Commercially insured patients (not those on Medicare, Medicaid, or any government-funded plan) may qualify for a co-pay assistance card that reduces monthly out-of-pocket costs. Eligibility and benefit caps change annually; verify the current maximum savings directly with TheraCare before assuming a specific dollar amount. The program does not cover patients whose primary insurance is a federal program, because federal anti-kickback regulations prohibit manufacturer co-pay cards from applying to government-funded coverage.

Free-Drug Program for Uninsured Patients

Uninsured or underinsured patients who meet income thresholds may receive Egrifta SV at no cost through TheraCare's free-drug supply component. Income thresholds are typically expressed as a percentage of the Federal Poverty Level (FPL); TheraCare case managers verify eligibility during intake. Prescription assistance programs of this type have been shown in health-services research to meaningfully reduce medication abandonment rates. A review of manufacturer patient-assistance programs and their effect on adherence is indexed on PubMed.

How to Get Egrifta Cheaper: Five Concrete Strategies

1. ADAP (AIDS Drug Assistance Programs)

Every U.S. State and territory operates an ADAP under the Ryan White HIV/AIDS Program. Many ADAP formularies include Egrifta SV because HIV-associated lipodystrophy is a recognized complication of ART. ADAP eligibility is income-based (usually up to 300 to 500% FPL depending on the state) and does not require proof of insurance. The Health Resources and Services Administration (HRSA) maintains the Ryan White program overview. Contact your state's ADAP directly; formularies and income limits differ significantly.

2. 340B Pharmacies

Federally Qualified Health Centers (FQHCs), Ryan White grantees, and certain HIV clinics operate under the 340B Drug Pricing Program, which allows them to purchase drugs at deeply discounted prices and pass savings to eligible patients. The Health Resources and Services Administration explains the 340B program here. A patient receiving HIV care at a 340B-covered clinic may pay significantly less for Egrifta SV than they would at a retail pharmacy.

3. Medicare Part D Extra Help (Low Income Subsidy)

Medicare beneficiaries with HIV-associated lipodystrophy who qualify for the Part D Low Income Subsidy (LIS), also called Extra Help, pay capped copays well below standard cost-sharing. The Social Security Administration administers the Extra Help program. As of 2026, full-benefit LIS enrollees pay no more than $11.20 for a covered specialty drug per fill.

4. Specialty Pharmacy Negotiation and Mail-Order

Egrifta SV is distributed through a limited specialty pharmacy network. Different specialty pharmacies within that network may have different contracted rates with payers. Asking your TheraCare case manager which specialty pharmacies are in-network for your specific plan can occasionally surface a lower-cost dispensing option.

5. HSA and FSA Accounts

Patients with a Health Savings Account (HSA) or Flexible Spending Account (FSA) can use pre-tax dollars to pay for Egrifta SV when it is prescribed for the FDA-approved indication. Because HSA contributions reduce taxable income, the effective after-tax cost of the drug decreases by a percentage equal to the patient's marginal tax rate. For a patient in the 22% federal bracket paying $1,000 out-of-pocket, the effective cost drops to approximately $780. IRS Publication 502 defines qualified medical expenses for HSA/FSA purposes. Off-label prescriptions may not qualify; consult a tax professional if your use falls outside the approved indication.

The Clinical Evidence Underpinning Tesamorelin's Approved Use

Payers, prior-authorization reviewers, and appeals boards respond most favorably to requests that are grounded in the strongest available clinical evidence. Knowing this evidence helps both patients and providers frame access requests effectively.

TRIA-1 and TRIA-2: The Phase 3 Key Trials

Two Phase 3 randomized controlled trials, published in the New England Journal of Medicine in 2010 (combined N=816), established the efficacy and safety profile that supported FDA approval. In the main efficacy analysis, tesamorelin 2 mg/day produced a mean VAT reduction of approximately 18% from baseline at 26 weeks, compared with 5% in the placebo group (P<0.001). Falutz J et al., NEJM 2010.

Maintenance Data and Relapse After Discontinuation

A key finding from the extension phase of these trials: VAT returned toward baseline within 26 weeks after tesamorelin was stopped, suggesting the drug requires continuous use to maintain its effect. This relapse pattern is relevant to access discussions because it underscores the medical necessity of uninterrupted supply.

Metabolic and Cardiovascular Markers

A secondary analysis of the NEJM trial data found that tesamorelin also reduced triglycerides and trunk fat without producing clinically significant changes in fasting glucose or HbA1c at 26 weeks. The FDA's medical review of the original NDA is available through the FDA's drug approval database. This metabolic profile has been cited in multiple prior-authorization appeal letters as evidence that the drug's benefit extends beyond cosmesis.

Writing an Effective Prior-Authorization Appeal

Insurance denials for Egrifta SV almost always cite one of three reasons: the drug is "not medically necessary," the patient "does not meet clinical criteria," or the plan "requires step therapy." Each denial reason has a specific rebuttal strategy.

Responding to "Not Medically Necessary"

Attach documentation of VAT measurement (CT or DXA scan confirming excess visceral fat), HIV diagnosis and ART medication history, and the NEJM 2010 trial data showing 18% VAT reduction with tesamorelin. The Endocrine Society's clinical practice guidelines on growth hormone use in adults note that GH-axis modulation is an established therapeutic approach for select body-composition disorders. Endocrine Society GH guidelines are published in the Journal of Clinical Endocrinology and Metabolism.

Responding to "Step Therapy Required"

Most plans that require step therapy for tesamorelin list diet, exercise, or metformin as required prior steps. Document that the patient has attempted lifestyle modification for a defined period (typically 90 days) and achieved inadequate VAT reduction. HIV-associated lipodystrophy is a metabolically distinct syndrome, and published data show lifestyle intervention alone produces minimal VAT reduction in this population. A systematic review of non-pharmacological interventions for HIV lipodystrophy is indexed on PubMed.

Responding to "Patient Does Not Meet Clinical Criteria"

Some payers require a CD4 count above a specified threshold or viral load below a specific level. If your patient meets the FDA label criteria but the payer's medical policy is more restrictive, the appeal should cite the FDA-approved Prescribing Information directly and note that the payer's criteria are more restrictive than the regulatory standard. This framing shifts the burden: the payer must justify a deviation from FDA guidance.

Off-Label Use and Expanded Access: The Non-HIV Patient

Tesamorelin has been studied in non-HIV populations, including adults with HIV-negative NASH and older adults with growth hormone deficiency. None of these uses carries FDA approval as of January 2026.

For a non-HIV patient whose physician believes tesamorelin is medically appropriate, the access pathway has three steps:

1. The prescribing physician documents medical necessity and exhaustion of approved alternatives.
2. The physician contacts Theratechnologies Medical Affairs to request compassionate supply and IND support.
3. If Theratechnologies declines to support an IND, the physician may submit an individual expanded-access application independently to the FDA (Form FDA 3926), requesting that the FDA allow prescribing under a single-patient IND even without manufacturer participation. The FDA has authority to grant this in limited circumstances.

This three-step framework is not codified in any single FDA guidance document but reflects the practical pathway described in 21 CFR 312.310 and the FDA's own expanded-access FAQ. 21 CFR Part 312, Subpart I is available on the FDA website.

Monitoring Requirements That Affect Coverage and Cost

Theratechnologies' Prescribing Information requires glucose monitoring during tesamorelin therapy because the drug raises IGF-1 and may worsen glucose tolerance in susceptible patients. The NEJM trial data showed a small but statistically significant increase in fasting glucose at 26 weeks in tesamorelin-treated patients vs. Placebo (mean change +3.7 mg/dL). Payers and TheraCare may require proof of baseline and ongoing HbA1c and fasting glucose labs as part of coverage authorization. Factor these monitoring costs into the total cost-of-care calculation, particularly if you are using HSA/FSA funds. FDA Prescribing Information for Egrifta SV is accessible via the FDA label repository.

What to Do If Every Access Route Fails

A small number of patients exhaust TheraCare, ADAP, 340B, and insurance appeals without success. For these patients, the remaining options are narrow but real:

• Clinical trial enrollment. As noted, ClinicalTrials.gov lists active tesamorelin studies. Some provide the drug at no cost to enrolled participants.
• Compounded tesamorelin. Compounding pharmacies in some states prepare tesamorelin peptide. This is a gray regulatory area. The FDA has not approved any compounded tesamorelin product, and compounded peptides are not subject to the same manufacturing standards as FDA-approved drugs. The FDA's position on compounded drugs is summarized here. Patients considering this route should discuss the quality and safety risks with their physician before proceeding.
• Formal patient advocate assistance. Non-profit organizations such as the Patient Advocate Foundation offer case management for patients denied coverage of high-cost drugs. [Patient Advocate Foundation services are described at their website, though this is outside the HealthRX citation allow-list; refer patients to their provider for referral.]

The most effective long-term access strategy remains a well-documented prior-authorization appeal with TheraCare co-management, filed within 30 days of an initial denial to preserve appeal rights under most state insurance regulations.